TABLE 1.
Characterization of native human anti-HA IBV MAbs
| MAb classification | MAb | Expression in HEK293 cellsa | HI activityb |
Neutralization in MDCK cellsc |
Predicted binding site, mode | Germ lined |
|||
|---|---|---|---|---|---|---|---|---|---|
| IBV Victoria | IBV Yamagata | IBV Victoria | IBV Yamagata | HC | LC | ||||
| Low expression | TRL798 | − | NDf | ND | ND | ND | ND | IGHV1-2*02 | IGKV1-6*01 |
| TRL834 | − | ND | ND | ND | ND | ND | IGHV1-69*12 | IGLV1-44*01 | |
| TRL851 | − | ND | ND | ND | ND | ND | IGHV5-51*01 | IGKV2D-28*01 | |
| HA head neutralizing | TRL809 | + | +/− | + | + | + | Head, neutg | IGHV3-30-3*02 | IGKV4-1*01 |
| TRL823 | + | + | + | + | + | Head, neut | IGHV3-43*02 | IGKV1-39*01 | |
| TRL832 | + | + | + | + | + | Head, neut | IGHV4-59*02 | IGLV3-1*01 | |
| TRL833 | + | + | + | + | + | Head, neut | IGHV4-31*03 | IGLV3-1*01 | |
| HA stalk nonneutralizing | TRL784 | + | − | − | − | − | Stalk, no neut | IGHV1-69*12 | IGLV3-21*02 |
| TRL799 | + | − | − | − | − | Stalk, no neut | IGHV1-2*02 | IGKV2D-28*01 | |
| TRL811 | + | − | − | − | − | Stalk, no neut | IGHV3-30*13 | IGKV1-17*01 | |
| TRL812 | + | +/− | − | +/− | +/− | Stalk, no neut | IGHV3-33*01 | IGKV3-15*01 | |
| TRL813 | + | − | − | +/− | +/− | Stalk, no neut | IGHV3-73*01 | IGKV1-5*03 | |
| TRL835 | + | − | − | − | − | Stalk, no neut | IGHV5-51*01 | IGKV2D-28*01 | |
| TRL837 | + | − | +/− | − | + | Stalk, no neut | IGHV1-69*12 | IGKV3-20*01 | |
| TRL841 | + | − | − | − | − | Stalk, no neut | IGHV3-30*18 | IGKV3-15*01 | |
| TRL842 | + | − | − | − | − | Stalk, no neut | IGHV3-30*18 | IGLV3-21*02 | |
| TRL846 | + | − | − | − | − | Stalk, no neut | IGHV3-23*04 | IGKV3-NL1*01 | |
| TRL856 | + | ND | − | − | − | Stalk, no neut | IGHV3-74*01 | IGLV3-21*02 | |
| HA stalk neutralizing | TRL845 | + | − | − | + | + | Stalk, neut | IGHV3-48*02 | IGKV1-9*01 |
| TRL847 | + | − | − | + | + | Stalk, neut | IGHV3-48*02 | IGKV1-9*01 | |
| TRL848 | + | − | − | + | + | Stalk, neut | IGHV3-30*18 | IGLV3-21*02 | |
| TRL849 | + | − | − | + | + | Stalk, neut | IGHV4-31*03 | IGKV3-15*01 | |
| TRL854 | + | − | − | + | + | Stalk, neut | IGHV1-2*02 | IGKV2D-28*01 | |
| Previously published MAbse | 5A7 | + | ND | ND | ND | ND | Stalk, neut | IGHV3-33*01 | IGLV1-47*02 |
| CR8033 | ND | ND | ND | ND | ND | Head, neut | IGHV3-9*01 | IGKV3-20*01 | |
| CR8071 | ND | ND | ND | ND | ND | Head, neut | IGHV1-18*01 | IGLV1-47*01 | |
| CR9114 | + | ND | ND | ND | ND | Stalk, no neut | IGHV1-69*06 | IGLV1-44*01 | |
a
Expression in HEK293 cells was classified as an expression level of >20 mg/liter (+) and an expression level of <20 mg/liter (−).
b
Hemagglutination inhibition activities against strains B/Victoria/2/1987 and B/Yamagata/16/1988 at effective MAb concentrations of 1.5 μg/ml (+), 200 μg/ml (+/−), and >200 μg/ml (−).
c
In vitro neut, in vitro neutralization IC50s against strains B/Victoria/2/1987 and B/Yamagata/16/1988 at MAb concentrations of ≤10 μg/ml (+) and >10 μg/ml (−).
d
Germ line families for the heavy chain (HC) and light chain (LC) are listed using the IMGT nomenclature (www.imgt.org).
f
ND, not determined.
g
neut, neutralization.